Knight Therapeutics Inc (GUD.TO)
23 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Knight Therapeutics Says Qtrly Basic Earnings Per Share $0.05
- BRIEF-Knight Therapeutics Announces Canadian Regulatory Approval For Probuphine For Opioid Drug Dependence
- BRIEF-Knight Therapeutics Says Will Have Exclusive Rights To Market And Sell Tenapanor In Canada
- BRIEF-Knight Reports Qtrly Basic Earnings Per Share $0.05
- BRIEF-Knight Therapeutics Says Medimetriks Pharma Has Prepaid $20 Mln Of Knight's $23 Mln Secured Strategic Loan Issued In 2016